Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Tucci

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Science Advances|January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphomaSara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Blood|September 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialEmanuele Zucca, Luca Ceriani, Giovannino Ciccone, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial ResultsMaurizio Martelli, Luca Ceriani, Giovannino Ciccone, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Blood|December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Science Advances|January 19, 2022
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphomaSara Rodriguez, Jon Celay, Ibai Goicoechea, et al.
Blood|September 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialEmanuele Zucca, Luca Ceriani, Giovannino Ciccone, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
The Lancet. Haematology|October 22, 2017
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2021
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiFrancesco Merli, Stefano Luminari, Alessandra Tucci, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Leukemia|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2024
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial ResultsMaurizio Martelli, Luca Ceriani, Giovannino Ciccone, et al.
Pageof 16